Page last updated: 2024-08-23

valrubicin and Carcinoma, Transitional Cell

valrubicin has been researched along with Carcinoma, Transitional Cell in 7 studies

Research

Studies (7)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (14.29)	18.2507
2000's	4 (57.14)	29.6817
2010's	2 (28.57)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Kamat, AM; Li, R; Spiess, PE	1
Barlow, LJ; Benson, MC	1
Bahnson, RR; Bamberger, MH; Bellingham, C; Childs, SJ; Edson, M; Giantonio, B; Greenberg, RE; Israel, M; O'Dwyer, PJ; Steinberg, GD; Sweatman, T; Wood, D	1
Baselli, EC; Greenberg, RE	1
Hetherington, J; Kisbenedek, L; Newling, DW; Robinson, MR; Sundaram, SK	1
Luciani, LG; Murphy, WM; Neulander, E; Wajsman, Z	1
Alsikafi, NF; Kuznetsov, DD; O'Connor, RC; Steinberg, GD	1

Reviews

3 review(s) available for valrubicin and Carcinoma, Transitional Cell

Article	Year
Experience with newer intravesical chemotherapy for high-risk non-muscle-invasive bladder cancer. Current urology reports, 2013, Volume: 14, Issue:2 Topics: Administration, Intravesical; Antineoplastic Agents; BCG Vaccine; Carcinoma, Transitional Cell; Deoxycytidine; Docetaxel; Doxorubicin; Gemcitabine; Humans; Mitomycin; Paclitaxel; Taxoids; Thiotepa; Treatment Failure; Urinary Bladder Neoplasms	2013
Intravesical therapy for superficial bladder cancer. Oncology (Williston Park, N.Y.), 2000, Volume: 14, Issue:5 Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; Anticarcinogenic Agents; Antineoplastic Agents; Carcinoma, Transitional Cell; Doxorubicin; Epirubicin; Humans; Interferons; Mitomycin; Mycobacterium bovis; Neoplasm, Residual; Photochemotherapy; Photosensitizing Agents; Thiotepa; Urinary Bladder Neoplasms	2000
Intravesical valrubicin in the treatment of carcinoma in situ of the bladder. Expert opinion on pharmacotherapy, 2001, Volume: 2, Issue:6 Topics: Administration, Intravesical; Antineoplastic Agents; Carcinoma in Situ; Carcinoma, Transitional Cell; Clinical Trials as Topic; Doxorubicin; Guidelines as Topic; Humans; Molecular Structure; Urinary Bladder Neoplasms	2001

Trials

2 trial(s) available for valrubicin and Carcinoma, Transitional Cell

Article	Year
Initial report on intravesical administration of N-trifluoroacetyladriamycin-14-valerate (AD 32) to patients with refractory superficial transitional cell carcinoma of the urinary bladder. Urology, 1997, Volume: 49, Issue:3 Topics: Administration, Intravesical; Aged; Aged, 80 and over; Anthracyclines; Carcinoma, Transitional Cell; Doxorubicin; Female; Humans; Male; Middle Aged; Urinary Bladder Neoplasms	1997
The use of valrubicin for the chemoresection of superficial bladder cancer -- a marker lesion study. European urology, 2001, Volume: 39, Issue:6 Topics: Administration, Intravesical; Aged; Carcinoma, Transitional Cell; Doxorubicin; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Time Factors; Urinary Bladder; Urinary Bladder Neoplasms	2001

Article

Year

Initial report on intravesical administration of N-trifluoroacetyladriamycin-14-valerate (AD 32) to patients with refractory superficial transitional cell carcinoma of the urinary bladder.

Urology, 1997, Volume: 49, Issue:3

Topics: Administration, Intravesical; Aged; Aged, 80 and over; Anthracyclines; Carcinoma, Transitional Cell; Doxorubicin; Female; Humans; Male; Middle Aged; Urinary Bladder Neoplasms

1997

The use of valrubicin for the chemoresection of superficial bladder cancer -- a marker lesion study.

European urology, 2001, Volume: 39, Issue:6

Topics: Administration, Intravesical; Aged; Carcinoma, Transitional Cell; Doxorubicin; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Time Factors; Urinary Bladder; Urinary Bladder Neoplasms

2001

Other Studies

2 other study(ies) available for valrubicin and Carcinoma, Transitional Cell

Article	Year
Treatment Options for Patients with Recurrent Tumors After BCG Therapy: Are We Ignoring the Obvious? European urology, 2018, Volume: 74, Issue:4 Topics: Adjuvants, Immunologic; Antineoplastic Agents; BCG Vaccine; Carcinoma, Transitional Cell; Clinical Trials as Topic; Cystectomy; Doxorubicin; Humans; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Patient Selection; Practice Guidelines as Topic; Urinary Bladder Neoplasms	2018
Risk of continued intravesical therapy and delayed cystectomy in BCG-refractory superficial bladder cancer: an investigational approach. Urology, 2001, Volume: 58, Issue:3 Topics: Administration, Intravesical; Aged; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Carcinoma, Transitional Cell; Cystectomy; Cystoscopy; Doxorubicin; Female; Follow-Up Studies; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Retrospective Studies; Secondary Prevention; Treatment Outcome; Urinary Bladder Neoplasms	2001

Article

Year

Treatment Options for Patients with Recurrent Tumors After BCG Therapy: Are We Ignoring the Obvious?

European urology, 2018, Volume: 74, Issue:4

Topics: Adjuvants, Immunologic; Antineoplastic Agents; BCG Vaccine; Carcinoma, Transitional Cell; Clinical Trials as Topic; Cystectomy; Doxorubicin; Humans; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Patient Selection; Practice Guidelines as Topic; Urinary Bladder Neoplasms

2018

Risk of continued intravesical therapy and delayed cystectomy in BCG-refractory superficial bladder cancer: an investigational approach.

Urology, 2001, Volume: 58, Issue:3

Topics: Administration, Intravesical; Aged; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Carcinoma, Transitional Cell; Cystectomy; Cystoscopy; Doxorubicin; Female; Follow-Up Studies; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Retrospective Studies; Secondary Prevention; Treatment Outcome; Urinary Bladder Neoplasms

2001